Literature DB >> 29667038

Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Flavia Storelli1,2, Caroline Samer1,3,4, Jean-Luc Reny3,5, Jules Desmeules1,2,3,4, Youssef Daali6,7,8,9.   

Abstract

Drug pharmacokinetics (PK) is influenced by multiple intrinsic and extrinsic factors, among which concomitant medications are responsible for drug-drug interactions (DDIs) that may have a clinical relevance, resulting in adverse drug reactions or reduced efficacy. The addition of intrinsic factors affecting cytochromes P450 (CYPs) activity and/or expression, such as genetic polymorphisms and diseases, may potentiate the impact and clinical relevance of DDIs. In addition, greater variability in drug levels and exposures has been observed when such intrinsic factors are present in addition to concomitant medications perpetrating DDIs. This variability results in poor predictability of DDIs and potentially dramatic clinical consequences. The present review illustrates the issue of complex DDIs using systematically searched published case reports of DDIs involving genetic polymorphisms, renal impairment, cirrhosis, and/or inflammation. Current knowledge on the impact of each of these factors on drug exposure and DDIs is summarized and future perspectives for the management of such complex DDIs in clinical practice are discussed, including the use of advanced Computerized Physician Order Entry (CPOE) systems, the development of model-based dose optimization strategies, and the education of healthcare professionals with respect to personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29667038     DOI: 10.1007/s40262-018-0650-9

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  204 in total

1.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.

Authors:  D Sutton; A M Butler; L Nadin; M Murray
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

2.  Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.

Authors:  Belén Valenzuela; Joseba Rebollo; Tania Pérez; Antonio Brugarolas; Juan José Pérez-Ruixo
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.

Authors:  Flavia Storelli; Alain Matthey; Sébastien Lenglet; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875

4.  Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.

Authors:  Matthieu Roustit; Emeline Blondel; Céline Villier; Xavier Fonrose; Michel P Mallaret
Journal:  Ann Pharmacother       Date:  2010-03-02       Impact factor: 3.154

5.  CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.

Authors:  J A Johnson; V L Herring; M S Wolfe; M V Relling
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

6.  Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.

Authors:  Patrice Forget; Bernard le Polain de Waroux; Pierre Wallemacq; Jean-Luc Gala
Journal:  J Pain Symptom Manage       Date:  2008-03-21       Impact factor: 3.612

7.  Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Authors:  Edward T Morgan; Kerry B Goralski; Micheline Piquette-Miller; Kenneth W Renton; Graham R Robertson; Madhusudana R Chaluvadi; Kellie A Charles; Stephen J Clarke; Marina Kacevska; Christopher Liddle; Terrilyn A Richardson; Rohini Sharma; Christopher J Sinal
Journal:  Drug Metab Dispos       Date:  2008-02       Impact factor: 3.922

8.  A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected].

Authors:  Ilaria Motta; Andrea Calcagno; Lorena Baietto; Antonio D'Avolio; Francesco Giuseppe De Rosa; Stefano Bonora
Journal:  Infez Med       Date:  2015-12

9.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Authors:  C H van der Wouden; A Cambon-Thomsen; E Cecchin; K C Cheung; C L Dávila-Fajardo; V H Deneer; V Dolžan; M Ingelman-Sundberg; S Jönsson; M O Karlsson; M Kriek; C Mitropoulou; G P Patrinos; M Pirmohamed; M Samwald; E Schaeffeler; M Schwab; D Steinberger; J Stingl; G Sunder-Plassmann; G Toffoli; R M Turner; M H van Rhenen; J J Swen; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

10.  Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.

Authors:  L J Rasmussen-Torvik; S C Stallings; A S Gordon; B Almoguera; M A Basford; S J Bielinski; A Brautbar; M H Brilliant; D S Carrell; J J Connolly; D R Crosslin; K F Doheny; C J Gallego; O Gottesman; D S Kim; K A Leppig; R Li; S Lin; S Manzi; A R Mejia; J A Pacheco; V Pan; J Pathak; C L Perry; J F Peterson; C A Prows; J Ralston; L V Rasmussen; M D Ritchie; S Sadhasivam; S A Scott; M Smith; A Vega; A A Vinks; S Volpi; W A Wolf; E Bottinger; R L Chisholm; C G Chute; J L Haines; J B Harley; B Keating; I A Holm; I J Kullo; G P Jarvik; E B Larson; T Manolio; C A McCarty; D A Nickerson; S E Scherer; M S Williams; D M Roden; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2014-06-24       Impact factor: 6.875

View more
  11 in total

1.  Sex-related differences in safety profiles, pharmacokinetics and tissue distribution of sinomenine hydrochloride in rats.

Authors:  Hong Huang; Er-Bing Zhang; Ou-Yang Yi; Han Wu; Guiming Deng; Yu-Ming Huang; Wen-Liang Liu; Jian-Ye Yan; Xiong Cai
Journal:  Arch Toxicol       Date:  2022-08-30       Impact factor: 6.168

2.  Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin-Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity.

Authors:  Wei Wu; Rui Cheng; Hamza Boucetta; Lei Xu; Jing-Ru Pan; Min Song; Yu-Ting Lu; Tai-Jun Hang
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

3.  An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.

Authors:  Andy R Eugene; Beata Eugene
Journal:  F1000Res       Date:  2018-05-30

4.  Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions.

Authors:  Flavia Storelli; Jules Desmeules; Youssef Daali
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-07-03

Review 5.  Cytochrome P450 Enzymes and Drug Metabolism in Humans.

Authors:  Mingzhe Zhao; Jingsong Ma; Mo Li; Yingtian Zhang; Bixuan Jiang; Xianglong Zhao; Cong Huai; Lu Shen; Na Zhang; Lin He; Shengying Qin
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

6.  CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function.

Authors:  Katalin Mangó; Ádám Ferenc Kiss; Ferenc Fekete; Réka Erdős; Katalin Monostory
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

Review 7.  Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.

Authors:  Yurong Song; Chenxi Li; Guangzhi Liu; Rui Liu; Youwen Chen; Wen Li; Zhiwen Cao; Baosheng Zhao; Cheng Lu; Yuanyan Liu
Journal:  Clin Pharmacokinet       Date:  2021-03-16       Impact factor: 6.447

8.  Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

Authors:  Mahmoud A El-Ghiaty; Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

9.  Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis.

Authors:  Mengyao Qin; Yu Xin; Yong Bian; Xuan Yang; Tao Xi; Jing Xiong
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600

10.  Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs.

Authors:  Youssef Daali; Amin Rostami-Hodjegan; Caroline F Samer
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.